Immunotherapy after surgery may keep melanoma from coming back
NCT ID NCT04013854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the immunotherapy drug nivolumab before and after surgery for stage III melanoma can help prevent the cancer from returning. About 67 adults with resectable melanoma will receive one dose of nivolumab before surgery, then after surgery they will get either nivolumab alone or a combination of nivolumab and ipilimumab for up to a year, based on how their tumor responded. The main goal is to see how long patients stay cancer-free after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Lancaster General Hospital
Lancaster, Pennsylvania, 17601, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?